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Rocuronium is a neuromuscular blocking agent acting as a competitive antagonist of acetylcholine. Re-
sults of an inhibition of eight individual liver microsomal cytochromes P450 (CYP) are presented. As the
patients are routinely premedicated with diazepam, possible interaction of diazepam with rocuronium
has been also studied.
Results indicated that rocuronium interacts with human liver microsomal CYPs by binding to the
substrate site. Next, concentration dependent inhibition of liver microsomal CYP3A4 down to 42% (at
rocuronium concentration 189 mM) was found. This effect has been conﬁrmed with two CYP3A4 sub-
strates, testosterone (formation of 6b-hydroxytestosterone) and diazepam (temazepam formation).
CYP2C9 and CYP2C19 activities were inhibited down to 75e80% (at the same rocuronium concentration).
Activities of other microsomal CYPs have not been inhibited by rocuronium.
To prove the possibility of rocuronium interaction with other drugs (diazepam), the effect of rocuro-
nium on formation of main diazepam metabolites, temazepam (by CYP3A4) and desmethyldiazepam,
(also known as nordiazepam; formed by CYP2C19) in primary culture of human hepatocytes has been
examined. Rocuronium has caused inhibition of both reactions by 20 and 15%, respectively.
The results open a possibility that interactions of rocuronium with drugs metabolized by CYP3A4 (and
possibly also CYP2C19) may be observed.
© 2014 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Rocuronium is a neuromuscular blocking agent (NMBA) acting
as a competitive antagonist of acetylcholine on the postsynaptic
nicotinic receptor of neuromuscular junction (1). Its advantage is
relatively quick onset of the neuromuscular block (the most quick
among currently used non-depolarizing NMBA, 60 s after 0.6mg/kg
dose) and an intermediate duration of its action (35e50 min after
the same dose) (1,2). Rocuronium is predominantly used to facili-
tate endotracheal intubation, to provide skeletal muscle relaxationhemistry and Biochemistry,




Production and hosting by Elsevieduring surgery, or to facilitate mechanical ventilation in intubated,
critically ill patients (1e3).
Rocuronium is according to its structure (Fig. 1) an aminosteroid
compound similar to vecuronium or pancuronium (1,2). It is in
principle a basic derivative of androstane with acetylated hydroxyl
group and with a substituent containing a quaternary nitrogen
atom; this is why the bromide salt is used in drug formulation.
Steroid nature of the molecule is an advantage as it is not a sub-
strate of pseudocholinesterase whose genetically determined
deﬁciency is a serious complicating factor causing prolonged
muscle relaxation e.g. after suxamethonium (succinylcholine)
(1e4). Primary route of rocuronium elimination is the liver re-
uptake and biliary excretion (5). Rocuronium is excreted from hu-
man organism in the urine (26% in 48 h), in the bile (7% in 48 h) and
in faeces (up to 31% during 7 days). Twometabolites of rocuronium
were found (5); 17-desacetylrocuronium is formed in relatively
small amount, this metabolite was found in the plasma, urine, bile
and faeces and in amount less than 10%. It was suggested that ar B.V. All rights reserved.
Fig. 1. Structure of rocuronium (1-allyl-1-(3a, 17bedihydroxy-2b-morpholino-5a-
androstan-16b-yl)pyrrolidinium bromide 17-acetate).
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reaction (6,7). An N-desallylrocuroniummetabolite was found to be
even less formed than the previous compound as it was detected in
the bile only, however, a study on formation of this metabolite is
lacking. As the amount of totally excreted rocuronium was below
75% of the doses, a formation of other (more polar) metabolites as
glucuronides cannot be ruled out (5).
Rocuronium, however, exhibits a great variability in the effect
and in the course of neuromuscular block as well in the time of
recovery. Variability of response to rocuronium is according to the
literature primarily caused by pharmacokinetics of this drug. In the
literature there are reports indicating that an interaction of
rocuronium with liver monooxygenase system of cytochromes
P450 (CYP) (8) may contribute to these differences (9). Also, in
patients with liver dysfunction or after application of inhalational
anesthetics, a decrease of the rocuronium clearance and increase of
elimination half-time have been observed (2); these effects may be
due to CYP-mediated formation of reactive species known to be
formed from inhalation anesthetics (10).
An increase in effect of rocuronium described after the use of
anesthetics (11) is not only the single example of interaction of other
drugs with rocuronium. Also, antibiotics as aminoglycosides (e.g.
gentamicin) and lincosamides (as clindamycin) poteniate neuro-
muscular blockade and should be used with caution (12,13). Inter-
estingly, clindamycin, metabolized by cytochrome P450 form 3A4
(CYP3A4), was found also to be an inhibitor of this form (14). On the
contrary, drugs known as inducers of CYP enzymes, e.g. carbamaz-
epine or phenytoin, appear to cause a decrease of the effect of
rocuronium (15). In general, the key for understanding drug in-
teractions may often be a dependence of drug (e.g. rocuronium)
levels on the activity of liver drug metabolizing enzymes (mostly
CYPs). In vitro studies on drug interactions are commonly used to
get an insight into the nature of these unwanted effects (16).
The present work is aimed to investigate the inﬂuence of
rocuroniumon the activities of the eight principal drug-metabolizing
enzymes, CYPs, of human liver microsomes (CYP1A2, 2A6, 2B6, 2C9,
2C19, 2D6, 2E1, 3A4). Asdiazepam(substrate of CYP3A4 andCYP2C19
(17)) is often used in premedication of the patients, in addition, mi-
crosomes and human hepatocytes were also used for studying of
possible drug interaction of rocuronium and diazepam.2. Material and methods
2.1. Materials
Rocuronium was obtained from N.V. Organon, Oss, Netherlands
(10 mg/ml). The structure of tested compound is shown in Fig. 1. 7-
Ethoxy-4-(triﬂuoromethyl)coumarin was supplied by Fluka (Buchs,
Switzerland). Acetonitril, methanol and HPLC column were from
Merck (Darmstadt, Germany). All other chemicals were purchasedfrom Sigma Aldrich CZ (Prague, Czech Republic). Pooled human liver
microsomes were obtained from Biopredic International (Rennes,
France).Microsomeswere from36 donors (25males and 11 females)
with a total cytochrome P450 content 582 pmol/mg of protein.
2.2. Spectral study of interaction of rocuronium with hepatic
microsomal CYP
Binding difference spectra of interactions of rocuronium with
microsomal CYP enzymes were followed according to established
procedure (18). The cuvette contained microsomes diluted to ﬁnal
concentration of CYP 1 mM in 50 mM potassium phosphate buffer
(pH 7.4). The tested compound was dissolved in 50 mM phosphate
buffer (pH 7.4) and the concentration range in experiments were
0e210 mM. Taking into account that rocuronium level in patients
reach routinely from 33 mM in plasma to 160 mM in the bile (after an
i.v. application of 0.3e0.9 mg kg1) (5), the concentration range
used here can be considered as adequate.
Spectra were recorded at room temperature by repetitive scan-
ning between 300 and 700 nm, at a scan speed of 150 nm/s. Baseline
of reference cuvette contained microsomes diluted to ﬁnal concen-
tration of CYP 1 mM in 50 mM K/PO4 buffer (pH 7.4). Spectra were
recorded on a Varian 4000 UV VIS spectrophotometer (Varian, Palo
Alto, USA). Absorbance change at about 418 nm was plotted against
concentration of compound tested. Datawere analyzed using a Sigma
Plot v. 8.0 graphing software (Jandel Scientiﬁc, Chicago, IL, USA).
2.3. Enzyme assays
The microsomal CYP activities were measured according to
established protocols. The following enzyme assays were per-
formed to determine activities of speciﬁc CYP enzymes: CYP1A2, 7-
ethoxyresoruﬁn O-deethylation (19); CYP2B6, 7-ethoxy-4-(tri-
ﬂuoromethyl)coumarin O-deethylation (20); CYP2C9, diclofenac 40-
hydroxylation (21), CYP2D6, bufuralol 10-hydroxylation (22);
CYP2E1, chlorzoxazone 6-hydroxylation (23); CYP3A4, testosterone
6b-hydroxylation (24) and diazepam 3-hydroxylation (see Method
for CYP2C19); CYP2A6, coumarin 7-hydroxylation (25). CYP2C19,
diazepam N-demethylation (http://www.cypex.co.uk/2c19info.
htm). Incubation mixtures contained 100 mM potassium phos-
phate buffer (pH 7.4) except for determination of CYP3A4 activity
(with substrate testosterone), where 50 mM Tris/KCl buffer, pH 7.4
was used, NADPH-generating system (0.8 mM NADPþ, 5.8 mM
isocitrate, 0.3 unit/mL of isocitrate dehydrogenase and 8 mM
MgCl2), human liver microsomes and individual probe substrate.
Time of incubation was 20 min.
For determination of metabolites formed from speciﬁc sub-
strates, HPLC system Shimadzu Class VP (Kyoto, Japan) with UV
detection or ﬂuorescence detection was used. As a rule, a reversed
phase chromatography was applied with Merck (Darmstadt, Ger-
many) LiChroCART 250  4 mm (i.d.) cartridges packed with a
LiChrospher RP-18 silica gel (5 mm particle size) with C-18 reversed
phase properties; a 4 4mm (i.d.) guard columnwas also used. For
composition of mobile phase in the respective analyses, see the
original literature, further details of the analyses incl. The concen-
trations of the respective substrates and experimental conditions
are presented in Table 1.
2.4. Enzyme inhibition studies
Initially, for each enzyme assay, a preliminary experiment was
done to determine Km and Vmax to obtain the appropriate concen-
tration of the speciﬁc substrates for the inhibition experiments
(substrate concentration was chosen in the range corresponding to
the value of the Km for each particular reaction). Datawere analyzed
Table 1
Experimental conditions for individual CYP enzyme activity assays.
CYP Substrate Substrate Incubation CYP pmol Quench agent Incubation Detection
Conc. (mM) Volume (mL) Time (min) HPLC
1A2 7-Ethoxyresoruﬁn 2.6 100 35 0.2 mL MetOH 15 Fluo
2A6 Coumarin 6.2 100 35 0.2 mL MetOH 15 Fluo
2B6 7-Ethoxy-4-(triﬂuoromethyl) 4 100 35 0.2 mL MetOH 15 Fluo
coumarin
2C9 Diclofenac 16 200 35 0.05 mL 94%ACN/ 25 UV
4% acetic acid
2D6 Bufuralol 13.2 200 70 0.02 mL 70% 15 Fluo
Perchloric acid
2E1 Chlorzoxazone 26 1000 160 0.05 mL 42% 15 UV
Phosphoric acid
3A4 Testosterone 100 500 100 2 mL dichlormethane 20 UV
2C19 and 3A4 Diazepam 100 200 70 0.1 mL ACN 20 UV
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studies. Inhibition experiments were performed with ﬁve concen-
tration levels of rocuronium (1.5, 5.9, 23.6, 94.4, 188.8 mM). As
rocuronium level in patients reach routinely from 33 mM in plasma
to 160 mM in the bile, the concentration range used here is adequate
(5). Experimental conditions were the same as for determination of
individual CYP activities; the assays were performed in three
separate experiments in duplicates with individual values differing
less than 10%. Statistical analyses were done as described in 2.6.
Preincubation of reaction mixtures with inhibitor (rocuronium) for
30 min at 37 C was kept in all assays. Inhibition of individual CYP
activities was in all cases evaluated by plotting respective remain-
ing activity against the inhibitor concentration.
2.5. Primary cultures of human hepatocytes
Primary cultures of human hepatocytes were prepared using
liver tissue obtained from multiorgan donors, for whom suitable
recipient was not available. Tissue acquisition protocol was in
accordance with requirements issued by local ethics committee of
the University Hospital, Olomouc, Czech Republic. Human liver
samples used in the experiments were from two donors; from each
liver sample, two experiments were performed. Hepatocytes were
isolated as previously described (26). Following isolation, the cells
were seeded on collagen-coated culture dishes at density
1.4  105 cells/cm2. Culture medium, made as described previously
(27), was enriched for seeding with 5% bovine serum (v/v). The
medium was exchanged for serum free medium (1.5 ml) the day
after and the culture was allowed to stabilize for an additional 48 h
prior to the treatment. Cultures were maintained at 37 C and 5%
CO2 in humidiﬁed incubator. Then rocuronium (ﬁnal concentration
100 mM), diazepam (ﬁnal concentration 50 mM) and both rocuro-
nium and diazepam (ﬁnal concentration 100 mM and 50 mM) were
applied to the medium and hepatocytes were incubated for 12 h.
Levels of both compounds corresponded to the values which may
be reached in patients (rocuronium, see above, diazepam, levels up
to 20e30 mMmay be found (28)). Diazepamwas added inmethanol
solution in concentrations for which the ﬁnal solvent concentration
did not exceed 0.5% (v/v) when added to incubation medium.
Substrates were absent in the control sample. Subsequently, 200 ml
sample was deproteinated by adding 100 ml of acetonitril. After
centrifugation at 9000 g for 10 min, supernatants (200 ml) were
subjected to HPLC analysis to detect diazepam metabolites.
2.6. Statistical analysis
All calculations were done using Microsoft Excel 2010 and Sta-
tistica 12 (Systat Software, San Jose, CA). One-way ANOVA followed
by t-test was used for the statistical evaluation of differencesbetween treated groups and control. The differences were regarded
as signiﬁcant when P < 0.05.
3. Results
3.1. Spectral studies of the rocuronium interaction with human liver
microsomal CYP enzymes
Spectral studies in the Soret region (Fig. 2) were used to detect
the substrate-induced difference spectra of cytochromes P450.
From the inspection of the course of the difference spectra for
tested compound it follows, that the rocuronium binds to human
liver microsomal CYP enzymes as substrate. The spectral change
corresponds to the formation of a minimum at about 420 nm
with a maximum formed at about 380 nm (Fig. 2). The value of
the corresponding spectroscopic binding constant (Ks) for tested
compound was 30.31 ± 9.31 mM. This value indicates the rela-
tively speciﬁc binding of rocuronium on microsomal cytochromes
P450.
3.2. Inhibition of speciﬁc CYP activities in human liver microsomes
In the present study, inhibitory effect of rocuronium on the ac-
tivities of eight microsomal CYP enzymes was investigated. Results
of the inhibition experiments are summarized in Fig. 3. Rocuronium
displayed no or weak inhibition of activities of CYP1A2, 2A6, 2B6,
2C9, 2D6 and 2E1. A moderate inhibitionwas observed for CYP2C19
(diazepam N-demethylation). Only the CYP3A4 activity was
inhibited signiﬁcantly. For measurement of the activity of CYP3A4,
metabolism of two different substrates was studied. Firstly,
testosterone with its speciﬁc metabolite 6b-hydroxytestosterone
and secondly diazepam with its speciﬁc metabolite temazepam
were used. In both cases rocuronium inhibited activity of CYP3A4
similarly. IC50 values for inhibition of testosterone hydroxylation
were found to be 115.8 mMand 108.6 mM for the second reaction, i.e.
for inhibition of temazepam formation.
3.3. Effect of rocuronium on metabolism of diazepam in human
hepatocytes
In hepatocytes, similarly to microsomes, diazepam is metabo-
lized to N-desmethyldiazepam by CYP2C19 (with contribution of
CYP3A4) and by CYP3A4 to temazepam, which are further metab-
olized and conjugated (17). Cytochrome P450 enzymes CYP2C19
and CYP3A4 are hence the main enzymes involved in the diazepam
metabolism. In this work, effect of rocuronium presence on for-
mation of both two main metabolites of diazepam formed in he-
patocytes was followed. Here, an advantagewas taken from the fact
that one substrate (diazepam) can be taken as a probe of activity of
Fig. 2. Spectral determination of interaction between rocuronium and cytochromes P450 in human liver microsomes. Insert, plot of the spectral difference (DA) at about 417 nm vs.
rocuronium concentration for determination of Ks (see text). Concentration of CYP in microsomal preparation, 1 mM in 50 mM K/phosphate buffer (pH 7.4).
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is a product of CYP2C19 and CYP3A4 and hydroxylated diazepam or
temazepam is formed by CYP3A4. Rocuronium, applied simulta-
neously with diazepam into primary culture of human hepatocytes,
slightly inhibited metabolism of diazepam. The concentration ofFig. 3. Effects of rocuronium on catalytic activities of CYP1A2, CYP2A6, CYP2B6,
CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 (3A4 I, substrate testosterone, 3A4 II,
substrate diazepam, for other substrates, see Methods, 2.3 and 2.4) enzymes in human
liver microsomes. Inhibition of catalytic activities is expressed as the activity remaining
relative to control (100%, without rocuronium) in percent. Concentration of rocuro-
nium in the reaction mixture was 0, 1.47, 5.90, 23.60, 94.4, and 188.8 mM. For experi-
mental details, see Methods (2.4 and 2.6). Activities represent the mean from three
independent experiments in duplicates and values signiﬁcantly different from control
are labeled (N ¼ 6, *P < 0.05, **P < 0.01).both diazepam metabolites was lower in this case by 11% for N-
desmethyldiazepam and by 15% for temazepam. Results are dis-
played in Fig. 4.Fig. 4. Inhibition of diazepam metabolism (formation of desmethyldiazepam and
temazepam) in the presence of rocuronium in primary human hepatocytes. Concen-
tration of diazepam, 50 mM; rocuronium, 100 mM; results shown as
means ± S.E.M.(bars); bars marked with an asterisk represent statistically signiﬁcant
results compared to control (N ¼ 4, P < 0.01, see Methods, 2.6 Statistical analysis).
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Results obtained in our study indicate that rocuronium interacts
with two forms of human liver microsomal CYPs. First, the differ-
ence spectra were employed to conﬁrm the presence of an inter-
action of rocuronium with (unspeciﬁed) microsomal CYPs. This
experiment is based on the fact, that in the liver microsomes, CYPs
are known to exist in an equilibrium between two forms with the
heme central ferric iron atom either in the high spin (approx.
390 nm absorption maximum in the absolute spectra) or low spin
(417 nm absorption maximum in the absolute spectrum) state. A
simpliﬁed explanation of the function of CYP enzymes begins with
binding of a substrate resulting in a conformational and structural
change in favor of the high spin form (8,10,18). Hence, in case a
substrate is bound, relative content of the high spin form increases,
which is reﬂected in formation of a maximum in the difference
spectrum corresponding to the high spin form (at about 390 nm);
concomitantly, a minimum in the difference spectrum is observed
at about 420 nm corresponding to a decrease of the low spin
content (18). Spectroscopic binding constant Ks (found in half
saturation in the plot of the absorbance change at selected wave-
length vs. substrate concentration, in analogy to the Km in enzyme
kinetics), expresses the relative afﬁnity of a substrate tomicrosomal
cytochromes P450. The results presented here (Fig. 2) (the value of
the spectroscopic binding constant Ks for rocuronium
30.31 ± 9.31 mM) indicated that there is a possibility of an inter-
action of rocuronium with human liver microsomal cytochrome
P450 enzymes.
In the next step, rocuronium was added to human microsomes
with the aim to ﬁnd the particular cytochrome P450 form with
which the tested compound interacts. Inhibition of speciﬁc activ-
ities of individual CYP enzymes by rocuronium was followed. The
results show (Fig. 3) that rocuronium was able to inhibit enzyme
activities of two forms of P450, namely, of the CYP3A4 and
CYP2C19. The activities of these two enzymes weremeasured using
their prototypic substrates: For CYP2C19, diazepam N-demethyla-
tion leading to formation of desmethyldiazepam metabolite was
used; to follow the activity of CYP3A4, inhibition of two activities
(testosterone 6b-hydroxylation and diazepam hydroxylation to
temazepam) was analyzed. The results conﬁrm the interaction of
rocuroniumwith both these activities. In fact, as the CYP3A4 form is
known to metabolize steroids and related compounds (as rocuro-
nium (6,7)), there is a possibility of binding of rocuronium to this
enzyme. In other words, concomitantly administered drugs
metabolized, or more generally, bound or interacting with CYP3A4
may contribute to a prolongation of rocuronium effect when they
are more strongly interacting with CYP3A4 than rocuronium itself.
This effect may in part contribute to increased sensitivity to
rocuronium during therapy with clindamycin which has been
alreadymentioned in the Introduction (13) as clindamycin has been
shown to be a substrate and inhibitor of the CYP3A4 enzyme (14).
The interactions of rocuronium described in this work may also
contribute to the shift of doseeresponse curve of rocuronium to
higher doses due to administration of diazepam in experimental
model (29) as well to prolonged effect of structurally very similar
vecuronium (30). It may be speculated that binding of diazepam to
CYP enzymes may also contribute to this effect as diazepam is a
substrate of both the CYP3A4 and CYP2C19 enzymes (17).
In summary, the results of spectral analysis of interaction (of the
sum of CYP enzymes present in the microsomal fraction of human
liver homogenate) with compound tested as well as studies on
inhibition of individual microsomal CYP activities by rocuronium
revealed an interaction indicating the binding of rocuronium to the
CYP enzymes. A detailed study on the possible inﬂuence of this
interaction to enzyme activities of eight individual CYP formsknown to be important for drug metabolism revealed signiﬁcant
interactions with CYP3A4 and CYP2C19. On the basis of these re-
sults with microsomal fraction, the attention was focused on
possible interactions of rocuronium and diazepam (substrate of
CYP3A4 as well as of CYP2C19). The experiments using human
hepatocytes indicated a possibility of drugedrug interaction when
rocuronium and diazepam are applied concurrently.
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